{"version":"1.0","provider_name":"Pharma Trend","provider_url":"https:\/\/pharma-trend.com\/en","author_name":"Business Wire","author_url":"https:\/\/pharma-trend.com\/en\/author\/business\/","title":"Nucleus Network Acquires Hammersmith Medicines Research - Pharma Trend","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"IjXWlAyoyQ\"><a href=\"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/\">Nucleus Network Acquires Hammersmith Medicines Research<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/embed\/#?secret=IjXWlAyoyQ\" width=\"600\" height=\"338\" title=\"&#8220;Nucleus Network Acquires Hammersmith Medicines Research&#8221; &#8212; Pharma Trend\" data-secret=\"IjXWlAyoyQ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/pharma-trend.com\/en\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"Establishes First Truly Global Early-Phase Clinical Trial Network BRISBANE, Australia &amp; LONDON&#8211;(BUSINESS WIRE)&#8211;Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom\u2019s most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network\u2019s global growth, establishing ... [Read more...]","thumbnail_url":"https:\/\/mms.businesswire.com\/media\/20250804665702\/en\/2542246\/22\/Nucleus_Network_Master_Logo_RGB.jpg"}